DK0699665T3 - Imidazolinderivater, deres fremstilling og deres anvendelse som tachykininreceptorantagonister - Google Patents
Imidazolinderivater, deres fremstilling og deres anvendelse som tachykininreceptorantagonisterInfo
- Publication number
- DK0699665T3 DK0699665T3 DK95303820T DK95303820T DK0699665T3 DK 0699665 T3 DK0699665 T3 DK 0699665T3 DK 95303820 T DK95303820 T DK 95303820T DK 95303820 T DK95303820 T DK 95303820T DK 0699665 T3 DK0699665 T3 DK 0699665T3
- Authority
- DK
- Denmark
- Prior art keywords
- alkyl
- alkylidenyl
- phenyl
- groups
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/257,966 US6175013B1 (en) | 1994-06-10 | 1994-06-10 | Imidazolinyl tachykinin receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0699665T3 true DK0699665T3 (da) | 2003-03-31 |
Family
ID=22978537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK95303820T DK0699665T3 (da) | 1994-06-10 | 1995-06-05 | Imidazolinderivater, deres fremstilling og deres anvendelse som tachykininreceptorantagonister |
Country Status (9)
Country | Link |
---|---|
US (1) | US6175013B1 (de) |
EP (1) | EP0699665B1 (de) |
JP (1) | JPH07330736A (de) |
AT (1) | ATE233737T1 (de) |
CA (1) | CA2151113A1 (de) |
DE (1) | DE69529790T2 (de) |
DK (1) | DK0699665T3 (de) |
ES (1) | ES2193171T3 (de) |
PT (1) | PT699665E (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2255910A1 (en) * | 1996-05-24 | 1997-11-27 | Mitchell Irvin Steinberg | Methods of treating hypertension |
DE19951701A1 (de) * | 1999-10-27 | 2001-05-03 | Aventis Pharma Gmbh | Verwendung von 2-Imidazolyl-substituierten Carbinolen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten |
CA2444395C (en) * | 2001-04-23 | 2010-12-21 | F. Hoffmann-La Roche Ag | Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
AU2002259147A1 (en) * | 2001-05-08 | 2002-11-18 | Schering Corporation | Use of neurokinin receptor antagonists to treat androgen-dependent diseases |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
JP4209332B2 (ja) * | 2002-02-01 | 2009-01-14 | エフ.ホフマン−ラ ロシュ アーゲー | α−1アゴニストとしての置換インドール |
PE20040600A1 (es) * | 2002-04-26 | 2004-09-15 | Lilly Co Eli | Derivados de triazol como antagonistas del receptor de taquicinina |
MXPA04010625A (es) * | 2002-04-26 | 2004-12-13 | Lilly Co Eli | Antagonista de receptor de taquicinina. |
US20060160794A1 (en) * | 2003-06-12 | 2006-07-20 | Amegadzie Albert K | Tachykinin receptor antagonists |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2505247A (en) | 1950-04-25 | Process fob the preparation of | ||
DE830954C (de) | 1949-04-06 | 1952-02-07 | Farbwerke Hoechst Vormals Meis | Verfahren zur Herstellung von Imidazolinen |
SU466231A1 (ru) | 1973-05-18 | 1975-04-05 | Московский Ордена Трудового Красного Знамени Институт Тонкой Химической Технологии Им.М.В.Ломоносова | Способ получени замещенных дигидроимидазолов или тетрагидропиримидинов |
EP0545478A1 (de) | 1991-12-03 | 1993-06-09 | MERCK SHARP & DOHME LTD. | Heterocyclische Verbindungen als Tachykininantagoniste |
GB9222262D0 (en) | 1992-10-23 | 1992-12-09 | Merck Sharp & Dohme | Therapeutic agents |
US6403577B1 (en) | 1993-11-17 | 2002-06-11 | Eli Lilly And Company | Hexamethyleneiminyl tachykinin receptor antagonists |
-
1994
- 1994-06-10 US US08/257,966 patent/US6175013B1/en not_active Expired - Fee Related
-
1995
- 1995-06-05 AT AT95303820T patent/ATE233737T1/de not_active IP Right Cessation
- 1995-06-05 PT PT95303820T patent/PT699665E/pt unknown
- 1995-06-05 ES ES95303820T patent/ES2193171T3/es not_active Expired - Lifetime
- 1995-06-05 DK DK95303820T patent/DK0699665T3/da active
- 1995-06-05 EP EP95303820A patent/EP0699665B1/de not_active Expired - Lifetime
- 1995-06-05 DE DE69529790T patent/DE69529790T2/de not_active Expired - Fee Related
- 1995-06-06 CA CA002151113A patent/CA2151113A1/en not_active Abandoned
- 1995-06-08 JP JP7141893A patent/JPH07330736A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JPH07330736A (ja) | 1995-12-19 |
EP0699665B1 (de) | 2003-03-05 |
ES2193171T3 (es) | 2003-11-01 |
PT699665E (pt) | 2003-06-30 |
ATE233737T1 (de) | 2003-03-15 |
EP0699665A1 (de) | 1996-03-06 |
DE69529790T2 (de) | 2003-11-06 |
US6175013B1 (en) | 2001-01-16 |
DE69529790D1 (de) | 2003-04-10 |
CA2151113A1 (en) | 1995-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0699665T3 (da) | Imidazolinderivater, deres fremstilling og deres anvendelse som tachykininreceptorantagonister | |
IL110131A0 (en) | Arylidene and heteroarylidene oxindole derivatives, their preparation and pharmaceutical compositions containing them | |
NO20021328L (no) | Pyrazolopyrimidier som terapeutiske midler | |
ZA200107533B (en) | Method of treating eating disorders. | |
AU4926301A (en) | Lpa receptor agonists and antagonists and methods of use | |
MXPA04000278A (es) | Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales. | |
ES2160525A1 (es) | Derivados de la 4-aroilpiperidina antagonistas de los receptores ccr-3 | |
PE41796A1 (es) | Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c. | |
DE60230424D1 (en) | Arylsulfonyl-derivate mit 5-ht 6-rezeptor-affinität | |
IL134894A (en) | 2-substituted-1,3,4,5-tetrahydro-2h-gamma-carbolines, their preparation and pharmaceutical compositions containing them | |
DK0732333T3 (da) | Indazolcarboxamider | |
NO20055515L (no) | 7-azaindoler og deres anvendelse som terapeutiske midler | |
DK0916670T3 (da) | Pyrrolo[3,2-b]pyridiner og deres anvendelse som 5-HT1f-agonister | |
MXPA05011476A (es) | Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2. | |
HK1074632A1 (en) | 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments | |
MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. | |
TW364908B (en) | Quinolone- and naphthyridonecarboxylic acid derivatives | |
IL100889A (en) | Nootropic and nerve- regenerative pharmaceutical compositions comprising 4-(7-bromo- 5-methoxybenzofuran-2-yl) piperidine | |
BG105427A (en) | Esters of (+)-alpha-(2,3-dimethyloxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pi peridinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 100,907 |